{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T13:49:53Z","timestamp":1782222593810,"version":"3.54.5"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006256","name":"Universit\u00e0 degli Studi dell\u2019Aquila","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006256","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lobaric and rhizocarpic acids are secondary metabolites isolated from Antarctic lichens. While several biological activities have been described for lobaric acid, the cellular effects of rhizocarpic acid remain poorly characterized. This study investigated the impact of these compounds on proliferation, apoptosis, and cell cycle regulation in human leukemic cell models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and Results<\/jats:title>\n                    <jats:p>\n                      Human leukemic K562 and MOLM-6 cells were exposed to lobaric and rhizocarpic acids under defined experimental conditions; cell viability, apoptosis, cell cycle distribution, and protein expression were evaluated using cell proliferation assays, flow cytometry, and western blot analysis. Both metabolites reduced cell growth and promoted caspase-dependent apoptosis in K562 and MOLM-6 cells. At the molecular level, in K562 cells, lobaric acid treatment was associated with increased Bax protein expression, whereas rhizocarpic acid induced upregulation of Bcl-2. In MOLM-6 cells, both compounds decreased STAT5 protein expression. In addition, both metabolites altered cell cycle distribution. Lobaric acid caused a significant increase of K562 cells in the G\n                      <jats:sub>2<\/jats:sub>\n                      \/M phase and a transient rise of MOLM-6 cells in G\n                      <jats:sub>1<\/jats:sub>\n                      phase, whereas rhizocarpic acid increased the proportion of cells in the G\n                      <jats:sub>1<\/jats:sub>\n                      phase, with a concomitant reduction in S and G\n                      <jats:sub>2<\/jats:sub>\n                      \/M populations in both leukemic cell lines. Analysis of cell cycle regulatory protein expression showed modulation of cyclin B1, cyclin D3, CDK4, and CDK6 by rhizocarpic acid, and upregulation of cyclin D3 by lobaric acid in both cell lines.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Overall, these findings provide new insights into the molecular mechanisms underlying the bioactivity of lichen-derived metabolites in leukemic cells and identify rhizocarpic acid as a previously uncharacterized modulator of apoptosis- and cell cycle-related pathway progression. Further studies, including comprehensive dose-response analyses and\n                      <jats:italic>in vivo<\/jats:italic>\n                      evaluations, will be necessary to fully define their therapeutic potential.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11033-026-12179-x","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T11:55:23Z","timestamp":1782215723000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pro-apoptotic and cell cycle-modulating effects of lobaric and rhizocarpic acids in human leukemic cell lines"],"prefix":"10.1007","volume":"53","author":[{"given":"Fabrizia","family":"Brisdelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Piccirilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Cinque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Celenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariagrazia","family":"Perilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"12179_CR1","doi-asserted-by":"publisher","first-page":"104283","DOI":"10.1016\/j.jff.2020.104283","volume":"80","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Mingfu W, Baojun X (2021) A comprehensive review on secondary metabolites and health-promoting effects of edible lichen. J Funct Food 80:104283","journal-title":"J Funct Food"},{"key":"12179_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s002530100684","volume":"56","author":"K M\u00fcller","year":"2001","unstructured":"M\u00fcller K (2001) Pharmaceutically relevant metabolites from lichens. Appl Microbiol Biotechnol 56:9\u201316","journal-title":"Appl Microbiol Biotechnol"},{"key":"12179_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-13374-4","volume-title":"Lichen Secondary Metabolites","author":"B Rankovi\u0107","year":"2015","unstructured":"Rankovi\u0107 B, Kosani\u0107 M (2015) Lichens as a potential source of bioactive secondary metabolites. In: Rankovi\u0107 B (ed) Lichen Secondary Metabolites. Springer International Publishing, Switzerland, pp 1\u201326"},{"key":"12179_CR4","first-page":"29","volume":"6","author":"S Bhattacharyya","year":"2016","unstructured":"Bhattacharyya S, Rani Deep PR, Singh S, Nayak B (2016) Lichen secondary metabolites and its biological activity. Am J PharmTech Res 6:29\u201344","journal-title":"Am J PharmTech Res"},{"key":"12179_CR5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/biom10010087","volume":"10","author":"Z Sol\u00e1rov\u00e1","year":"2020","unstructured":"Sol\u00e1rov\u00e1 Z, Liskova A, Samec M, Kubatka P, B\u00fcsselberg D, Sol\u00e1r P (2020) Anticancer potential of lichens\u2019 secondary metabolites. Biomolecules 10:87","journal-title":"Biomolecules"},{"key":"12179_CR6","doi-asserted-by":"publisher","first-page":"941","DOI":"10.4103\/0973-1482.177218","volume":"14","author":"B Emsen","year":"2018","unstructured":"Emsen B, Aslan A, Turkez H, Joughi A, Kaya A (2018) The anti-cancer efficacies of diffractaic, lobaric, and usnic acid: in vitro inhibition of glioma. J Cancer Res Ther 14:941\u2013951","journal-title":"J Cancer Res Ther"},{"key":"12179_CR7","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/ptr.4739","volume":"27","author":"F Brisdelli","year":"2013","unstructured":"Brisdelli F, Perilli M, Sellitri D, Piovano M, Garbarino JA, Nicoletti M, Bozzi A, Amicosante G, Celenza G (2013) Cytotoxic activity and antioxidant capacity of purified lichen metabolites: an in vitro study. Phytother Res 27:431\u2013437","journal-title":"Phytother Res"},{"key":"12179_CR8","doi-asserted-by":"publisher","first-page":"658","DOI":"10.3390\/molecules23030658","volume":"23","author":"JM Hong","year":"2018","unstructured":"Hong JM, Suh SS, Kim TK, Kim JE, Han SJ, Youn UJ, Yim JH, Kim IC (2018) Anti-cancer activity of lobaric acid and lobarstin extracted from the antarctic lichen Stereocaulon alpnum. Molecules 23:658","journal-title":"Molecules"},{"key":"12179_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.2042-7158.1998.tb03312.x","volume":"50","author":"HM \u00d6gmundsd\u00f3ttir","year":"1998","unstructured":"\u00d6gmundsd\u00f3ttir HM, Zo\u00ebga GM, Gissurarson SR, Ingolfsd\u00f3ttir K (1998) Anti-proliferative effects of lichen-derived inhibitors of 5-lipoxygenase on malignant cell-lines and mitogen-stimulated lymphocytes. J Pharm Pharmacol 50:107\u2013115","journal-title":"J Pharm Pharmacol"},{"key":"12179_CR10","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1055\/s-2004-832657","volume":"70","author":"S Haraldsd\u00f3ttir","year":"2004","unstructured":"Haraldsd\u00f3ttir S, Guolaugsd\u00f3ttir E, Ing\u00f3lfsd\u00f3ttir K, Ogmundsd\u00f3ttir HM (2004) Anti-proliferative effects of lichen-derived lipoxygenase inhibitors on twelve human cancer cell lines of different tissue origin in vitro. Planta Med 70:1098\u20131100","journal-title":"Planta Med"},{"key":"12179_CR11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41571-023-00840-4","volume":"21","author":"L Morrison","year":"2024","unstructured":"Morrison L, Loibl S, Turner NC (2024) The CDK4\/6 inhibitor revolution a game-changing era for breast cancer treatment. Nat Rev Clin Oncol 21:89\u2013105","journal-title":"Nat Rev Clin Oncol"},{"key":"12179_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1639\/0007-2745-113.1.1","volume":"113","author":"M Hauck","year":"2010","unstructured":"Hauck M, J\u00fcrgens SR, Leuschner C (2010) Effect of amino acid moieties on metal binding in pulvinic acid derivatives and ecological implications for lichens producing these compounds. Bryologist 113:1\u20137","journal-title":"Bryologist"},{"key":"12179_CR13","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1055\/s-2006-957070","volume":"73","author":"T Kokubun","year":"2007","unstructured":"Kokubun T, Shiu WKP, Gibbons S (2007) Inhibitory activities of lichen-derived compounds against methicillin- and multidrug-resistant staphylococcus aureus. Planta Med 73:176\u2013179","journal-title":"Planta Med"},{"key":"12179_CR14","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1021\/acs.jnatprod.2c01013","volume":"86","author":"PJC James","year":"2023","unstructured":"James PJC, Vuong D, Moggach SA, Lacey E, Piggott MJ (2023) Synthesis, characterization, and bioactivity of the lichen pigments pulvinamide, rhizocarpic acid, and epanorin and congeners. J Nat Prod 86:550\u2013556","journal-title":"J Nat Prod"},{"key":"12179_CR15","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","volume":"96","author":"MW Deininger","year":"2000","unstructured":"Deininger MW, Goldman JM, Melo JV (2000) The molecular biology of chronic myeloid leukemia. Blood 96:3343\u20133356","journal-title":"Blood"},{"key":"12179_CR16","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nrc1567","volume":"5","author":"R Ren","year":"2005","unstructured":"Ren R (2005) Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 5:172\u2013183","journal-title":"Nat Rev Cancer"},{"key":"12179_CR17","doi-asserted-by":"publisher","unstructured":"Khajapeeri KV, Baskaran R (2016) Natural products for treatment of chronic myeloid leukemia. In: Baankovic J (ed) Anti-cancer Drugs: Nature, Synthesis and Cell. IntechOperm Publisher. https:\/\/doi.org\/10.5772\/66175","DOI":"10.5772\/66175"},{"key":"12179_CR18","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3390\/biom11030392","volume":"11","author":"MT Kabir","year":"2021","unstructured":"Kabir MT, Rahman MH, Akter R, Behl T, Kaushik D, Mittal V, Pandey P, Akhtar MF, Saleem A, Albadrani GM, Kamel M, Khalifa SAM, El-Seedi HR, Abdel-Daim MM (2021) Potential role of curcumin and its nanoformulations to treat various types of cancers. Biomolecules 11:392","journal-title":"Biomolecules"},{"key":"12179_CR19","first-page":"75","volume":"39","author":"W Quilhot","year":"1989","unstructured":"Quilhot W, Garbarino JA, Piovano M, Chamy MC, Gambaro V, Oyarz\u00fan ML, Vinet C, Hormaechea V, Fiedler P (1989) Studies on chilean lichens. XI. Secondary metabolites from antarctic lichens. Ser Cient INACH 39:75\u201389","journal-title":"Ser Cient INACH"},{"key":"12179_CR20","first-page":"79","volume":"41","author":"M Piovano","year":"1991","unstructured":"Piovano M, Garbarino JA, Chamy MC, Z\u00fa\u00f1iga V, Miranda C, C\u00e9spedes E, Fiedler P, Quilhot W, Araya G (1991) Studies on chilean lichens. XVI. Advances in the chemistry of secondary metabolites from antarctic lichens. Ser Cient INACH 41:79\u201390","journal-title":"Ser Cient INACH"},{"key":"12179_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"T Mosmann","year":"1983","unstructured":"Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55\u201363","journal-title":"J Immunol Methods"},{"key":"12179_CR22","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","volume":"72","author":"MM Bradford","year":"1976","unstructured":"Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248\u2013254","journal-title":"Anal Biochem"},{"key":"12179_CR23","first-page":"115","volume":"22","author":"H Tripathi","year":"2022","unstructured":"Tripathi H, Negi N, Gahtori R, Kumari A, Joshi P, Tewari LM, Joshi Y, Bajpai R, Upreti DK, Upadhyay SK (2022) A review of anti-cancer and related properties of lichen-extracts and metabolites. Anticancer Agents Med Chem 22:115\u2013142","journal-title":"Anticancer Agents Med Chem"},{"key":"12179_CR24","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1055\/a-1482-6381","volume":"88","author":"I Ure\u00f1a-Vacas","year":"2022","unstructured":"Ure\u00f1a-Vacas I, Gonz\u00e1lez-Burgos E, Divakar PK, G\u00f3mez-Serranillos MP (2022) Lichen depsidones with biological interest. Planta Med 88:855\u2013880","journal-title":"Planta Med"},{"key":"12179_CR25","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/nrc2718","volume":"9","author":"S Polager","year":"2009","unstructured":"Polager S, Ginsberg D (2009) p53 and E2f: partners in life and death. Nat Rev Cancer 9:738\u2013748","journal-title":"Nat Rev Cancer"},{"key":"12179_CR26","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/nrm.2016.27","volume":"17","author":"P Hydbring","year":"2016","unstructured":"Hydbring P, Malumbres M, Sicinski P (2016) Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases. Nat Rev Mol Cell Biol 17:280\u2013292","journal-title":"Nat Rev Mol Cell Biol"},{"key":"12179_CR27","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2005-01-0034","volume":"106","author":"PL Bergsagel","year":"2005","unstructured":"Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr (2005) Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106:296\u2013303","journal-title":"Blood"},{"key":"12179_CR28","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/nrc2602","volume":"9","author":"M Malumbres","year":"2009","unstructured":"Malumbres M, Barbacid M (2009) Cell cycle, CDKs and cancer: A changing paradigm. Nat Rev Cancer 9:53\u2013166","journal-title":"Nat Rev Cancer"},{"key":"12179_CR29","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.phrs.2018.11.035","volume":"139","author":"R Roskoski Jr","year":"2019","unstructured":"Roskoski R Jr (2019) Cyclin-dependent protein serine\/threonine kinase inhibitors as anticancer drugs. Pharmacol Res 139:471\u2013488","journal-title":"Pharmacol Res"},{"key":"12179_CR30","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1158\/1535-7163.MCT-14-1065","volume":"15","author":"A Nemoto","year":"2016","unstructured":"Nemoto A, Saida S, Kato I, Kikuchi J, Furukawa Y, Maeda Y, Akahane K, Honna-Oshiro H, Goi K, Kagami K, Kimura S, Sato Y, Okabe S, Niwa A, Watanabe K, Nakahata T, Heike T, Sugita K, Inukai T (2016) Specific antileukemic activity of PD0332, a CDK4\/6inhibitor, against Philadelphia chromosome positive lymphoid leukemia. Mol Cancer Ther 15:94\u2013105","journal-title":"Mol Cancer Ther"},{"key":"12179_CR31","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ebiom.2019.11.004","volume":"50","author":"M Schneeweiss-Gleixner","year":"2019","unstructured":"Schneeweiss-Gleixner M, Byrgazov K, Stefanzi G, Berger D, Eisenwort G, Lucini CB, Herndlhofer S, Preuner S, Obrova K, Pusic P, Witzeneder N, Greiner G, Hoermann G, Sperr WR, Lion T, Deininger M, Valent P, Gleixner KV (2019) CDK4\/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I\u2009+\u2009clones in TKI-resistant CML. EBioMedicine 50:111\u2013121","journal-title":"EBioMedicine"},{"key":"12179_CR32","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.3390\/genes12091355","volume":"12","author":"P Porazzi","year":"2021","unstructured":"Porazzi P, de Dominicis M, Salvino J, Calabretta B (2021) targeting the CDK6 dependence of Ph+ acute lymphoblastic leukemia. Genes 12:1355","journal-title":"Genes"},{"key":"12179_CR33","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1038\/s41417-024-00747-x","volume":"31","author":"X Wang","year":"2024","unstructured":"Wang X, Zhao S, Xin Q, Zhang Y, Wang K (2024) Recent progress of CDK4\/6 inhibitors\u2019 current practice in breast cancer. Cancer Gene Ther 31:1283\u20131291","journal-title":"Cancer Gene Ther"},{"key":"12179_CR34","doi-asserted-by":"publisher","first-page":"34676","DOI":"10.1074\/jbc.274.49.34676","volume":"274","author":"GJ Boonen","year":"1999","unstructured":"Boonen GJ, van Oirschot BA, van Diepen A, Mackus WJ, Verdonck LF, Rijksen G, Medema RH (1999) Cyclin D3 regulates proliferation and apoptosis of leukemic T cell lines. J Biol Chem 274:34676\u201334682","journal-title":"J Biol Chem"},{"key":"12179_CR35","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1242\/dev.091744","volume":"140","author":"S Lim","year":"2013","unstructured":"Lim S, Kaldis P (2013) Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development 140:3079\u20133093","journal-title":"Development"},{"key":"12179_CR36","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1158\/0008-5472.CAN-05-3389","volume":"66","author":"AM Eglof","year":"2006","unstructured":"Eglof AM, Vella LA, Finn OJ (2006) Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer. Cancer Res 66:6\u20139","journal-title":"Cancer Res"},{"key":"12179_CR37","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1038\/sj.onc.1205257","volume":"21","author":"N Sarafan-Vasseur","year":"2002","unstructured":"Sarafan-Vasseur N, Lamy A, Bourguignon J, Le Pessot F, Hieter P, Sesbo\u00fc\u00e9 R, Bastard C, Fr\u00e9bourg T, Flaman JM (2002) Overexpression of B-type cyclins alters chromosomal segregation. Oncogene 21:2051\u20132057","journal-title":"Oncogene"},{"key":"12179_CR38","doi-asserted-by":"publisher","first-page":"5245","DOI":"10.1128\/MCB.16.10.5245","volume":"16","author":"RU Janicke","year":"1996","unstructured":"Janicke RU, Lin XY, Lee FH, Porter AG (1996) Cyclin D3 sensitizes tumor cells to tumor necrosis factor-induced, c-Myc-dependent apoptosis. Mol Cell Biol 16:5245\u20135253","journal-title":"Mol Cell Biol"},{"key":"12179_CR39","doi-asserted-by":"publisher","first-page":"6871","DOI":"10.1073\/pnas.072290599","volume":"99","author":"AR Mendelsohn","year":"2002","unstructured":"Mendelsohn AR, Hamer JD, Wang ZB, Brent R (2002) Cyclin D3 activates Caspase 2, connecting cell proliferation with cell death. Proc Natl Acad Sci USA 99:6871\u20136876","journal-title":"Proc Natl Acad Sci USA"},{"key":"12179_CR40","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3390\/biomedicines8090316","volume":"8","author":"CE Halim","year":"2020","unstructured":"Halim CE, Deng S, Ong MS, Yap CT (2020) Involvement of STAT5 in oncogenesis. Biomedicines 8:316","journal-title":"Biomedicines"},{"key":"12179_CR41","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/emmm.201000062","volume":"2","author":"A Hoelbl","year":"2010","unstructured":"Hoelbl A, Schuster C, Kovacic B, Zhu B, Wickre M, Hoelzl MA, Fajmann S, Grebien F, Warsch W, Stengl G, Hennighausen L, Poli V, Beug H, Moriggl R, Sexl V (2010) Stat5 is indispensable for the maintenance of bcr\/abl-positive leukaemia. EMBO Mol Med 2:98\u2013110","journal-title":"EMBO Mol Med"},{"key":"12179_CR42","doi-asserted-by":"publisher","first-page":"4720","DOI":"10.4049\/jimmunol.159.10.4720","volume":"159","author":"SK Chai","year":"1997","unstructured":"Chai SK, Nichols GL, Rothman P (1997) Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol 159:4720\u20134728","journal-title":"J Immunol"},{"key":"12179_CR43","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1182\/blood-2009-10-248211","volume":"117","author":"W Warsch","year":"2011","unstructured":"Warsch W, Kollmann K, Eckelhart E, Fajmann S, Cerny-Reiterer S, H\u00f6lbl A, Gleixner KV, Dworzak M, Mayerhofer M, Hoermann G, Herrmann H, Sillaber C, Egger G, Valent P, Moriggl R, Sexl V (2011) High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood 117:3409\u20133420","journal-title":"Blood"},{"key":"12179_CR44","doi-asserted-by":"publisher","first-page":"5793","DOI":"10.1158\/0008-5472.CAN-18-0195","volume":"78","author":"V Minieri","year":"2018","unstructured":"Minieri V, De Dominici M, Porazzi P, Mariani SA, Spinelli O, Rambaldi A, Peterson LF, Porcu P, Nevalainen MT, Calabretta B (2018) Targeting STAT5 or STAT5-regulated pathways suppresses leukemogenesis of Ph+ acute lymphoblastic leukemia. Cancer Res 78:5793\u20135807","journal-title":"Cancer Res"},{"key":"12179_CR45","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1182\/blood-2002-11-3490","volume":"102","author":"CP Shelburne","year":"2003","unstructured":"Shelburne CP, McCoy ME, Piekorz R, Sexl V, Roh KH, Jacobs-Helber SM, Gillespie SR, Bailey DP, Mirmonsef P, Mann MN, Kashyap M, Wright HV, Chong HJ, Bouton LA, Barnstein B, Ramirez CD, Bunting KD, Sawyer S, Lantz CS, Ryan JJ (2003) Stat5 expression is critical for mast cell development and survival. Blood 102:1290\u20131297","journal-title":"Blood"},{"key":"12179_CR46","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1182\/blood.V88.3.809.809","volume":"88","author":"RM Weber-Nordt","year":"1996","unstructured":"Weber-Nordt RM, Egen C, Wehinger J, Ludwig W, Gouilleux-Gruart V, Mertelsmann R, Finke J (1996) Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood 88:809\u2013816","journal-title":"Blood"},{"key":"12179_CR47","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1182\/blood-2002-03-0740","volume":"101","author":"M Buitenhuis","year":"2003","unstructured":"Buitenhuis M, Baltus B, Lammers JW, Coffer PJ, Koenderman L (2003) Signal transducer and activator of transcription 5a (STAT5a) is required for eosinophil differentiation of human cord blood-derived CD34\u2009+\u2009cells. Blood 101:134\u2013142","journal-title":"Blood"},{"key":"12179_CR48","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.exphem.2003.09.014","volume":"31","author":"JW Snow","year":"2003","unstructured":"Snow JW, Abraham N, Ma MC, Bronson SK, Goldsmith MA (2003) Transgenic bcl-2 is not sufficient to rescue all hematolymphoid defects in STAT5A\/5B-deficient mice. Exp Hematol 31:1253\u20131258","journal-title":"Exp Hematol"},{"key":"12179_CR49","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1084\/jem.191.6.977","volume":"191","author":"M Horita","year":"2000","unstructured":"Horita M, Andreu EJ, Benito A, Arbona C, Sanz C, Benet I, Prosper F, Fernandez-Luna JL (2000) Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med 191:977\u2013984","journal-title":"J Exp Med"},{"key":"12179_CR50","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1006\/mcbr.2000.0231","volume":"3","author":"RP de Groot","year":"2000","unstructured":"de Groot RP, Raaijmakers JA, Lammers JW, Koenderman L (2000) STAT5-Dependent Cyclin D1 and Bcl-xL expression in Bcr-Abl-transformed cells. Mol Cell Biol Res Commun 3:299\u2013305","journal-title":"Mol Cell Biol Res Commun"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12179-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12179-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12179-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T13:05:13Z","timestamp":1782219913000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12179-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12179"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12179-x","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"9 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"977"}}